Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy

Cancer Immunol Immunother. 1983;15(3):172-7. doi: 10.1007/BF00199160.

Abstract

In two parallel studies, bitches with mammary tumour received single intralesional injections of BCG (1 mg: 10(7) living bacteria) and Corybacterium parvum (10(9) killed bacteria) (53 bitches) or C. parvum alone (129 bitches) at the same dosage. Control groups received injections, following the same protocol, of 1 ml BCG suspension medium diluted in saline in the first study (51 bitches) or no injections at all (120 bitches in the second study). A block dissection, including mammary tumours, adjacent mammary glands, and regional lymph nodes, was performed 2 weeks later in all animals. On the basis of histologically confirmed malignant tumours, 48 bitches (25 treated by-immunotherapy and 23 controls) in the first study and 67 bitches (30 treated by immunotherapy and 37 controls) in the second study remained for postsurgical follow-up. The clinical tolerance of the treatment was generally good. No significant differences were found in cumulative survival rates between treated and control group in either studies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Animals
  • Autopsy
  • BCG Vaccine / therapeutic use
  • Body Weight
  • Dogs
  • Female
  • Immunotherapy
  • Lymphatic Metastasis
  • Mammary Neoplasms, Experimental / therapy*
  • Mastectomy
  • Prognosis
  • Propionibacterium acnes / immunology

Substances

  • BCG Vaccine